This site uses cookies to improve your experience and to provide services and advertising. By continuing to browse, you agree to the use of cookies described in our Cookies Policy. You may change your settings at any time but this may impact on the functionality of the site. To learn more see our Cookies Policy.
OK
Dublin: 13 °C Wednesday 16 October, 2019
Advertisement

EU investigates if company increased cancer drug prices by 'several hundred percent'

In Italy in 2016, Aspen Pharma increased the price of five “life-saving and irreplaceable” drugs by between 300% and 1,500%.

Image: Shutterstock/CI Photos

THE EUROPEAN UNION has launched an investigation into drugs giant Aspen Pharma over suspicions that the company charges excessive prices for life-saving cancer medicine.

The European Commission, the EU’s executive arm, “will investigate whether Aspen has abused a dominant market position in breach of EU antitrust rules,” it said in a statement.

The case is the Commission’s first investigation into allegations of excessive pricing practices in the pharmaceutical industry.

The probe involves South African pharmaceutical company Aspen’s pricing for five medicines used for treating various types of cancer, including leukemia, non-Hodgkin lymphoma and multiple myeloma.

“When the price of a drug suddenly goes up by several hundred percent, this is something the Commission may look at,” EU Competition Commissioner Magrethe Vestager said in a statement.

shutterstock_325249841 Source: Shutterstock/ESB Professional

According to BEUC, the European Consumer Organisation, these drugs are “life-saving and irreplaceable” and especially used by children and elderly people.

BEUC requested an EU-wide investigation in 2016 after Aspen was fined €5 million for excessive pricing by Italian authorities in a case involving the same drugs.

In Italy, Aspen had adopted a particularly aggressive negotiating strategy, obtaining price increases ranging between 300% and 1,500%.

“Consumers rely on drug companies to recover from illnesses and in many cases save their lives. Big pharma players should not abuse this dependence which is exactly what such price policies seem to do,” BEUC said in a statement.

In a statement, ASPEN said it could not comment on the proceedings but “takes compliance with competition laws very seriously and will work constructively with the European Commission in its process.”

© – AFP 2017

Read: ‘This story is false’: White House denies Trump shared highly classified information with Russia

Read: These two EU heavyweights met today (and they want even more eurozone integration)

  • Share on Facebook
  • Email this article
  •  

About the author:

AFP

Read next:

COMMENTS (18)